

2015-462 3D Scaffolds for Mesoderm Differentiation

Published date: Aug. 28, 2019

Technology description

SUMMARY

Researchers led by Benjamin Wu from the Departments of Bioengineering and Pathology & Laboratory Medicine have developed an implantable scaffolding that can create hematopoietic stem cells from pluripotent stem cells *in vivo*.

BACKGROUND

Hematopoietic stem cells (HSC) produce all cell types of the blood, including immune cells, and can be found in the blood and bone marrow. Transplantation of HSC' s from healthy donors can treat a variety of diseases that include: leukemia, sickle cell disease, organ rejection, and autoimmune diseases (multiple sclerosis, lupus). Mismatches between donor and recipient can cause an autoimmune response that require hospitalization and can be fatal. To circumvent this problem, the patient' s own pluripotent stem cells (PSC) can be used to create HSC' s. However, this has only been done in a dish with poor results. HSC' s created this way do not proliferate very well and the engraftment does not integrate with the patient' s body very well.

INNOVATION

Researchers led by Benjamin Wu from the Departments of Bioengineering and Pathology & Laboratory Medicine have developed an implantable scaffolding that can create hematopoietic stem cells from pluripotent stem cells *in vivo*. Current *in vitro* approaches lack the microenvironment and timing of complex signals, especially mechanical signals due to blood flow, to produce stable HSC' s. A proof of concept study has shown that HSC' s can be derived *in vivo* by tumors that developed from PSC' s. These bioengineers have improved on this concept by using specialized PSC' s that do not have the potential to form tumors and have seeded them onto an implantable 3D scaffold. These scaffolds can be 3D printed with unique shapes and biomaterials to tailor fit the needs of the individual patient. Preliminary data has shown that this approach can produce stable HSC' s without the risks that stem from donor transplantation and with greater efficiency than current *in vitro* approaches.

Application area

Treatment of blood disorders like leukemia and sickle cell disease

Treatment of immune diseases (lupus, multiple sclerosis, and diabetes)

Treatment of organ transplant rejections

Advantages

In vivo approach allows for stronger and more natural HSC production and integration

Use of patient's own stem cells prevent donor-recipient mismatches and complications

3D scaffolding can be customizable to the patient and his or her condition

Institution

[University of California, Los Angeles](#)

Inventors

[Gay Crooks](#)

Professor

PATH

[Denis Evseenko](#)

Asst Prof In-Res

ORTHO SURG

[Chee Jia Chin](#)

PATH

[Eric Tsang](#)

SURG

[Benjamin Wu](#)

Professor

Dentistry

联系我们



叶先生

电话：021-65679356

手机：13414935137

邮箱：yeyingsheng@zf-ym.com